The University of Texas Health

1. AstraZeneca Pharmaceuticals LP $3,249,275 5 payments
2. Ultragenyx Pharmaceutical Inc. $465,369 58 payments
3. Amgen Inc. $433,829 8 payments
4. CSL Behring $432,725 52 payments
5. Genentech, Inc. $324,810 20 payments
6. Novocure GmbH $314,337 52 payments
7. United Therapeutics Corporation $166,548 58 payments
8. Novocure Inc. $110,410 24 payments
9. ViiV Healthcare Company $110,248 23 payments
10. Global Blood Therapeutics, Inc. $98,920 25 payments

1. Phase II Single Arm Study of Tremelimumab and Durvalumab T300 D in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis STRIDE in CP-B $3,161,947 3 payments
2. A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding $403,678 35 payments
3. EF-32 TRIDENT A Pivotal Randomized, Open -Label Study of Tumor Treating Fields (Optune, 200khz) Concomitant with Radiation Therapy and Temazolomde for the Treatment of New Diagnosed Glioblastoma $314,337 52 payments
4. Dtx401-Cl301 $213,301 13 payments
5. Phase 2 Double Blind Randomized Study in IPF and SSc ILD $182,697 15 payments
6. P2b HZN-825-301 dcSSc BEACON $113,230 1 payment
7. Ux053-Cl101 $105,813 13 payments
8. Ph1b to evaluate GDC 1971 furmonertinib in EGFRmt NSCLC $98,053 1 payment
9. A Phase 3B, Open Label, Randomized, Standard-Of-Care Control Arm, Mult $85,817 9 payments
10. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $84,578 1 payment

1. Patient care $25,118 3 payments
2. Other $10,720 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.